Osteopore Limited announce the appointment of Carl Runde as Chief Financial Officer of the Company. Mr. Runde has more than twenty years of international medical device industry experience in corporate financial analysis, valuation modelling, and strategic business planning. Mr. Runde was previously Vice President Finance - Corporate Systems and FP&A for ResMed, a leading medical device company providing cloud-connectable devices for the treatment of sleep apnea and other respiratory disorders. Mr. Runde held executive finance positions at ResMed from 2003 to 2019, working within multiple divisions across the Asia Pacific. Most recently Mr. Runde has completed his PhD and worked as an independent financial consultant for medical technology start-ups. Based in Sydney, Mr. Runde will oversee all financial operations of Osteopore with a focus on facilitating growth and ensuring the creation of sustainable stakeholder value. Mr. Runde will also manage the Company's Investor Relations and Corporate communications Coinciding with Mr. Runde's appointment, Mr. Geoff Pocock will transition from his executive role at Osteopore to a Non- Executive Director role over the coming months. Mr. Pocock will remain as a member of Osteopore's Board, and will assist in the transition of Mr. Runde to become Osteopore's new primary point of contact for Australian capital markets.